Professor Kevin Blyth
- Professor of Respiratory Medicine/Honorary Consultant in Respiratory Medicine (Clinical Research Garscube)
- Honorary Professor (School of Cancer Sciences)
telephone:
0141 330 3180
email:
Kevin.Blyth@glasgow.ac.uk
Room 236a, Level 2, Wolfson Wohl Cancer Research Centre, Switchback Road, Bearsden, Glasgow, G61 1BD
Biography
Kevin Blyth is Professor of Respiratory Medicine in Glasgow.
Following completion of Internal and Respiratory Medicine training and the award of an MD in Magnetic Resonance Imaging he was appointed as a Consultant in 2009.
He splits his time between the CRUK Beatson Institute/University of Glasgow and the Queen Elizabeth University Hospital, where he leads the Glasgow Pleural Disease Unit.
He founded and is Director of the Macmillan Scottish Mesothelioma Network, which coordinates clinical care and access to clinical trials for Mesothelioma patients in Scotland.
He is an NHS Scotland Research (NRS) Senior Research Fellow and leads a translational research program focused on pleural disease and thoracic malignancy, and has a particular interest in Mesothelioma.
He is Principal Investigator of the CRUK PREDICT-Meso International Accelerator Network.
Publications
2024
Frankell, A. M. et al. (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631(8022), E15. (doi: 10.1038/s41586-024-07738-w) (PMID:38965439)
Blyth, K. G. et al. (2024) Leveraging the pleural space for anticancer therapies in pleural mesothelioma. Lancet Respiratory Medicine, 12(6), pp. 476-483. (doi: 10.1016/S2213-2600(24)00111-5) (PMID:38740045)
Neilly, M., Ferguson, K., Roche, J., Tate, M. and Blyth, K. (2024) Mesothelioma Evolution following a Diagnosis of Benign Pleural Inflammation: A Systematic Review and Meta-Analysis. 22nd Annual British Thoracic Oncology Group Conference, Belfast, UK, 17-19 April 2024. p. 107626. (doi: 10.1016/j.lungcan.2024.107626)
Hassan, M., Touman, A. A., Grabczak, E. M., Skaarup, S. H., Faber, K., Blyth, K. G. and Pochepnia, S. (2024) Imaging of pleural disease. Breathe, 20(1), 230172. (doi: 10.1183/20734735.0172-2023) (PMID:38482187) (PMCID:PMC10928554)
Tárnoki, Á. D., Tárnoki, D. L., Dąbrowska, M., Knetki-Wróblewska, M., Frille, A., Stubbs, H. , Blyth, K. G. and Juul, A. D. (2024) New developments in the imaging of lung cancer. Breathe, 20(1), 230176. (doi: 10.1183/20734735.0176-2023) (PMID:38595936) (PMCID:PMC11003524)
Morrow, A. J. et al. (2024) Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization. Communications Medicine, 4, 32. (doi: 10.1038/s43856-024-00455-5) (PMID:38418616) (PMCID:PMC10901805)
Catarata, M. J. et al. (2024) ERS International Congress 2023: highlights from the Thoracic Oncology Assembly. ERJ Open Research, 10(1), 860-2023. (doi: 10.1183/23120541.00860-2023) (PMID:38410708) (PMCID:PMC10895436)
2023
Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)
Ferguson, J. et al. (2023) Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): Protocol of a prospective, multicentre, observational study. BMJ Open Respiratory Research, 10, e001771. (doi: 10.1136/bmjresp-2023-001771) (PMID:37996118) (PMCID:PMC10668291)
Ferguson, K. et al. (2023) Results of the Meso-ORIGINS feasibility study regarding collection of matched benign-mesothelioma tissue pairs by longitudinal surveillance. BMJ Open, 13, e067780. (doi: 10.1136/bmjopen-2022-067780) (PMID:37553196) (PMCID:PMC10414089)
Farahmand, P. et al. (2023) Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. Frontiers in Toxicology, 5, 1200650. (doi: 10.3389/ftox.2023.1200650) (PMID:37441092) (PMCID:PMC10333928)
Abbosh, C. et al. (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616(7957), pp. 553-562. (doi: 10.1038/s41586-023-05776-4) (PMID:37055640)
Al Bakir, M. et al. (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616, pp. 534-542. (doi: 10.1038/s41586-023-05729-x) (PMID:37046095) (PMCID:PMC10115651)
Frankell, A. M. et al. (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616, pp. 525-533. (doi: 10.1038/s41586-023-05783-5) (PMID:37046096) (PMCID:PMC10115649)
Martínez-Ruiz, C. et al. (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616, pp. 543-552. (doi: 10.1038/s41586-023-05706-4) (PMID:37046093) (PMCID:PMC10115639)
Ng, K. W. et al. (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616, pp. 563-573. (doi: 10.1038/s41586-023-05771-9) (PMID:37046094) (PMCID:PMC10115647)
Hill, W. et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616(7955), pp. 159-167. (doi: 10.1038/s41586-023-05874-3) (PMID:37020004)
Al-Sawaf, O. et al. (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29(4), pp. 846-858. (doi: 10.1038/s41591-023-02232-8) (PMID:37045997) (PMCID:PMC7614477)
Karasaki, T. et al. (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29(4), pp. 833-845. (doi: 10.1038/s41591-023-02230-w) (PMID:37045996) (PMCID:PMC7614478)
Katz, S. I. et al. (2023) Considerations for imaging of malignant pleural mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Journal of Thoracic Oncology, 18(3), pp. 278-298. (doi: 10.1016/j.jtho.2022.11.018) (PMID:36549385)
Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)
2022
Kidd, A. C., Anderson, O., Cowell, G. W. , Weir, A. J., Voisey, J. P., Evison, M., Tsim, S., Goatman, K. A. and Blyth, K. G. (2022) Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. Thorax, 77(12), pp. 1251-1259. (doi: 10.1136/thoraxjnl-2021-217808) (PMID:35110367)
Conway, R. J. H., Symonds, J., Walton, D., Probets, J., Comins, C., Stadon, L., Harvey, J. E., Blyth, K. G. , Maskell, N. A. and Bibby, A. C. (2022) Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso). BMJ Open, 12(11), e060850. (doi: 10.1136/bmjopen-2022-060850) (PMID:36357003) (PMCID:PMC9660577)
Bedawi, E. O. et al. (2022) The impact of the COVID-19 pandemic on pleural infection incidence: a UK multicentre retrospective analysis. ERJ Open Research, 8(3), 00206-2022. (doi: 10.1183/23120541.00206-2022) (PMID:35919861) (PMCID:PMC9235054)
Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)
Rosas, I. O. et al. (2022) Tocilizumab in patients hospitalised with COVID-19 pneumonia: efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine, 47, 101409. (doi: 10.1016/j.eclinm.2022.101409) (PMID:35475258) (PMCID:PMC9022847)
Quinn, T. M. et al. (2022) Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBioMedicine, 76, 103856. (doi: 10.1016/j.ebiom.2022.103856) (PMID:35152152) (PMCID:PMC8831100)
2021
McPeake, J. et al. (2021) Long-term outcomes following severe COVID-19 infection: a multicentre cohort study of family member outcomes. Annals of the American Thoracic Society, 18(12), pp. 2098-2101. (doi: 10.1513/AnnalsATS.202104-481RL) (PMID:34192506) (PMCID:PMC8641813)
Berry, C. et al. (2021) Post-COVID-19 illness trajectory: a multisystem investigation [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1053331/v1)
Asciak, R. et al. (2021) The association between pleural fluid exposure and survival in pleural mesothelioma. Chest, 160(5), pp. 1925-1933. (doi: 10.1016/j.chest.2021.05.063) (PMID:34119515)
Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)
Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109(4), pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003) (PMID:33309910) (PMCID:PMC7726525)
McPeake, J. et al. (2021) Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study. BMJ Open Respiratory Research, 8, e001080. (doi: 10.1136/bmjresp-2021-001080)
2020
Mangion, K. et al. (2020) The Chief Scientist Office cardiovascular and pulmonary imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 116(14), pp. 2185-2196. (doi: 10.1093/cvr/cvaa209) (PMID:32702087) (PMCID:PMC7454350)
Tsim, S., Cowell, G. W. , Kidd, A., Woodward, R., Alexander, L., Kelly, C. , Foster, J. E. and Blyth, K. G. (2020) A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 150, pp. 12-20. (doi: 10.1016/j.lungcan.2020.09.025) (PMID:33039775)
Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)
Duffy, C. et al. (2020) Chest drain aerosol generation in COVID-19 and emission reduction using a simple anti-viral filter. BMJ Open, 7, e000710. (doi: 10.1136/bmjresp-2020-000710) (PMID:33148778) (PMCID:PMC7643431)
Ferguson, K., Quail, N., Kewin, P. and Blyth, K. G. (2020) COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis. BMJ Case Reports, 13(8), e237460. (doi: 10.1136/bcr-2020-237460) (PMID:32747597) (PMCID:PMC7401579)
AbdulJabbar, K. et al. (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26(7), pp. 1054-1062. (doi: 10.1038/s41591-020-0900-x) (PMID:32461698)
Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)
Ferguson, J. et al. (2020) Staging by Thoracoscopy in Potentially Radically Treatable Non-Small Cell Lung Cancer Associated with Minimal Pleural Effusion (STRATIFY) study: a prospective multicentre study. Lung Cancer, 139(1), S92. (doi: 10.1016/S0169-5002(20)30245-2)
2019
Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C. , Holme, J., Evison, M. and Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017) (PMID:31200818)
Cunningham, Y., Wyke, S. , Blyth, K. G. , Rigg, D., Macdonald, S. , Macleod, U., Harrow, S., Robb, K. A. and Whitaker, K. L. (2019) Lung cancer symptom appraisal among people with chronic obstructive pulmonary disease: a qualitative interview study. Psycho-Oncology, 28(4), pp. 718-725. (doi: 10.1002/pon.5005) (PMID:30693608) (PMCID:PMC6492269)
2018
Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3(6), e000408. (doi: 10.1136/esmoopen-2018-000408) (PMID:30233821) (PMCID:PMC6135448)
Martin, G. A. , Tsim, S., Kidd, A. C., Foster, J. E., McLoone, P. , Chalmers, A. and Blyth, K. G. (2018) Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respiratory Research, 5(1), e000293. (doi: 10.1136/bmjresp-2018-000293) (PMID:29862030) (PMCID:PMC5976095)
Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)
Blyth, K. G. and Murphy, D. J. (2018) Progress and challenges in Mesothelioma: from bench to bedside. Respiratory Medicine, 134, pp. 31-41. (doi: 10.1016/j.rmed.2017.11.015)
Cherrie, J. W., McElvenny, D. and Blyth, K. G. (2018) Estimating past inhalation exposure to asbestos: a tool for risk attribution and disease screening. International Journal of Hygiene and Environmental Health, 221(1), pp. 27-32. (doi: 10.1016/j.ijheh.2017.09.013) (PMID:29030093)
Haughney, J., Morice, A., Blyth, K. G. , Lee, A. J., Coutts, A., McKnight, E. and Pavord, I. (2018) A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels. Respiratory Medicine, 134, pp. 117-123. (doi: 10.1016/j.rmed.2017.12.001) (PMID:29413497)
Kidd, A. C., McGettrick, M., Tsim, S., Halligan, D. L., Bylesjo, M. and Blyth, K. G. (2018) Survival prediction in mesothelioma using a scalable lasso regression model: instructions for use and initial performance using clinical predictors. BMJ Open Respiratory Research, 5(1), e000240. (doi: 10.1136/bmjresp-2017-000240) (PMID:29468073) (PMCID:PMC5812388)
Sharma, V. and Blyth, K. G. (2018) Empyema necessitans and a persistent air leak associated with rupture of an anaerobic lung abscess due to bacteroides. Thorax, 73(1), pp. 91-93. (doi: 10.1136/thoraxjnl-2017-210462) (PMID:28847872)
Evison, M. et al. (2018) Providing safe and effective pleural medicine services in the UK: an aspirational statement from UK pleural physicians. BMJ Open Respiratory Research, 5, e000307. (doi: 10.1136/bmjresp-2018-000307) (PMID:30116537) (PMCID:PMC6089266)
2017
Murphy, D. J. and Blyth, K. G. (2017) Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'. Cell Death and Differentiation, 24(9), pp. 1473-1474. (doi: 10.1038/cdd.2017.97) (PMID:28622291)
Blyth, K. G. , Bellofiore, A., Jayasekera, G. , Foster, J. E., Steedman, T., Chesler, N. C. and Peacock, A. J. (2017) Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival. Pulmonary Circulation, 7(2), pp. 465-475. (doi: 10.1177/2045893217704838) (PMID:28597775) (PMCID:PMC5467938)
Tsim, S., Stobo, D. B., Alexander, L., Kelly, C. and Blyth, K. G. (2017) The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 103, pp. 38-43. (doi: 10.1016/j.lungcan.2016.11.010) (PMID:28024694) (PMCID:PMC5226066)
2016
Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)
Armato, S. G., Blyth, K. G. , Keating, J. J., Katz, S., Tsim, S., Coolen, J., Gudmundsson, E., Opitz, I. and Nowak, A. K. (2016) Imaging in pleural mesothelioma: a review of the 13th International Conference of the International Mesothelioma Interest Group. 2016 International Conference of the International Mesothelioma Interest Group (iMig), Birmingham, UK, 01-04 May 2016. pp. 48-58. (doi: 10.1016/j.lungcan.2016.09.003)
2015
Blyth, K. G. (2015) Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax, 70(4), p. 374. (doi: 10.1136/thoraxjnl-2014-206464) (PMID:25480442)
Articles
Frankell, A. M. et al. (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631(8022), E15. (doi: 10.1038/s41586-024-07738-w) (PMID:38965439)
Blyth, K. G. et al. (2024) Leveraging the pleural space for anticancer therapies in pleural mesothelioma. Lancet Respiratory Medicine, 12(6), pp. 476-483. (doi: 10.1016/S2213-2600(24)00111-5) (PMID:38740045)
Hassan, M., Touman, A. A., Grabczak, E. M., Skaarup, S. H., Faber, K., Blyth, K. G. and Pochepnia, S. (2024) Imaging of pleural disease. Breathe, 20(1), 230172. (doi: 10.1183/20734735.0172-2023) (PMID:38482187) (PMCID:PMC10928554)
Tárnoki, Á. D., Tárnoki, D. L., Dąbrowska, M., Knetki-Wróblewska, M., Frille, A., Stubbs, H. , Blyth, K. G. and Juul, A. D. (2024) New developments in the imaging of lung cancer. Breathe, 20(1), 230176. (doi: 10.1183/20734735.0176-2023) (PMID:38595936) (PMCID:PMC11003524)
Morrow, A. J. et al. (2024) Socioeconomic deprivation and illness trajectory in the Scottish population after COVID-19 hospitalization. Communications Medicine, 4, 32. (doi: 10.1038/s43856-024-00455-5) (PMID:38418616) (PMCID:PMC10901805)
Catarata, M. J. et al. (2024) ERS International Congress 2023: highlights from the Thoracic Oncology Assembly. ERJ Open Research, 10(1), 860-2023. (doi: 10.1183/23120541.00860-2023) (PMID:38410708) (PMCID:PMC10895436)
Berry, C. et al. (2023) Mental health symptoms and illness trajectory following COVID-19 hospitalization: A cohort study. Heart and Mind, 7(4), pp. 235-245. (doi: 10.4103/hm.HM-D-23-00037)
Ferguson, J. et al. (2023) Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): Protocol of a prospective, multicentre, observational study. BMJ Open Respiratory Research, 10, e001771. (doi: 10.1136/bmjresp-2023-001771) (PMID:37996118) (PMCID:PMC10668291)
Ferguson, K. et al. (2023) Results of the Meso-ORIGINS feasibility study regarding collection of matched benign-mesothelioma tissue pairs by longitudinal surveillance. BMJ Open, 13, e067780. (doi: 10.1136/bmjopen-2022-067780) (PMID:37553196) (PMCID:PMC10414089)
Farahmand, P. et al. (2023) Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. Frontiers in Toxicology, 5, 1200650. (doi: 10.3389/ftox.2023.1200650) (PMID:37441092) (PMCID:PMC10333928)
Abbosh, C. et al. (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616(7957), pp. 553-562. (doi: 10.1038/s41586-023-05776-4) (PMID:37055640)
Al Bakir, M. et al. (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616, pp. 534-542. (doi: 10.1038/s41586-023-05729-x) (PMID:37046095) (PMCID:PMC10115651)
Frankell, A. M. et al. (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616, pp. 525-533. (doi: 10.1038/s41586-023-05783-5) (PMID:37046096) (PMCID:PMC10115649)
Martínez-Ruiz, C. et al. (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616, pp. 543-552. (doi: 10.1038/s41586-023-05706-4) (PMID:37046093) (PMCID:PMC10115639)
Ng, K. W. et al. (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616, pp. 563-573. (doi: 10.1038/s41586-023-05771-9) (PMID:37046094) (PMCID:PMC10115647)
Hill, W. et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616(7955), pp. 159-167. (doi: 10.1038/s41586-023-05874-3) (PMID:37020004)
Al-Sawaf, O. et al. (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29(4), pp. 846-858. (doi: 10.1038/s41591-023-02232-8) (PMID:37045997) (PMCID:PMC7614477)
Karasaki, T. et al. (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29(4), pp. 833-845. (doi: 10.1038/s41591-023-02230-w) (PMID:37045996) (PMCID:PMC7614478)
Katz, S. I. et al. (2023) Considerations for imaging of malignant pleural mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Journal of Thoracic Oncology, 18(3), pp. 278-298. (doi: 10.1016/j.jtho.2022.11.018) (PMID:36549385)
Sykes, R. et al. (2023) Adjudicated myocarditis and multisystem illness trajectory in healthcare workers post-COVID-19. Open Heart, 10(1), e002192. (doi: 10.1136/openhrt-2022-002192) (PMID:36822817) (PMCID:PMC9950584)
Kidd, A. C., Anderson, O., Cowell, G. W. , Weir, A. J., Voisey, J. P., Evison, M., Tsim, S., Goatman, K. A. and Blyth, K. G. (2022) Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. Thorax, 77(12), pp. 1251-1259. (doi: 10.1136/thoraxjnl-2021-217808) (PMID:35110367)
Conway, R. J. H., Symonds, J., Walton, D., Probets, J., Comins, C., Stadon, L., Harvey, J. E., Blyth, K. G. , Maskell, N. A. and Bibby, A. C. (2022) Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso). BMJ Open, 12(11), e060850. (doi: 10.1136/bmjopen-2022-060850) (PMID:36357003) (PMCID:PMC9660577)
Bedawi, E. O. et al. (2022) The impact of the COVID-19 pandemic on pleural infection incidence: a UK multicentre retrospective analysis. ERJ Open Research, 8(3), 00206-2022. (doi: 10.1183/23120541.00206-2022) (PMID:35919861) (PMCID:PMC9235054)
Morrow, A. J. et al. (2022) A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 28(6), pp. 1303-1313. (doi: 10.1038/s41591-022-01837-9) (PMID:35606551) (PMCID:PMC9205780)
Rosas, I. O. et al. (2022) Tocilizumab in patients hospitalised with COVID-19 pneumonia: efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine, 47, 101409. (doi: 10.1016/j.eclinm.2022.101409) (PMID:35475258) (PMCID:PMC9022847)
Quinn, T. M. et al. (2022) Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBioMedicine, 76, 103856. (doi: 10.1016/j.ebiom.2022.103856) (PMID:35152152) (PMCID:PMC8831100)
McPeake, J. et al. (2021) Long-term outcomes following severe COVID-19 infection: a multicentre cohort study of family member outcomes. Annals of the American Thoracic Society, 18(12), pp. 2098-2101. (doi: 10.1513/AnnalsATS.202104-481RL) (PMID:34192506) (PMCID:PMC8641813)
Berry, C. et al. (2021) Post-COVID-19 illness trajectory: a multisystem investigation [Pre-print]. Research Square, (doi: 10.21203/rs.3.rs-1053331/v1)
Asciak, R. et al. (2021) The association between pleural fluid exposure and survival in pleural mesothelioma. Chest, 160(5), pp. 1925-1933. (doi: 10.1016/j.chest.2021.05.063) (PMID:34119515)
Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16(10), pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018) (PMID:34116230) (PMCID:PMC8514249)
Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109(4), pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003) (PMID:33309910) (PMCID:PMC7726525)
McPeake, J. et al. (2021) Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study. BMJ Open Respiratory Research, 8, e001080. (doi: 10.1136/bmjresp-2021-001080)
Mangion, K. et al. (2020) The Chief Scientist Office cardiovascular and pulmonary imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 116(14), pp. 2185-2196. (doi: 10.1093/cvr/cvaa209) (PMID:32702087) (PMCID:PMC7454350)
Tsim, S., Cowell, G. W. , Kidd, A., Woodward, R., Alexander, L., Kelly, C. , Foster, J. E. and Blyth, K. G. (2020) A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 150, pp. 12-20. (doi: 10.1016/j.lungcan.2020.09.025) (PMID:33039775)
Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)
Duffy, C. et al. (2020) Chest drain aerosol generation in COVID-19 and emission reduction using a simple anti-viral filter. BMJ Open, 7, e000710. (doi: 10.1136/bmjresp-2020-000710) (PMID:33148778) (PMCID:PMC7643431)
Ferguson, K., Quail, N., Kewin, P. and Blyth, K. G. (2020) COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis. BMJ Case Reports, 13(8), e237460. (doi: 10.1136/bcr-2020-237460) (PMID:32747597) (PMCID:PMC7401579)
AbdulJabbar, K. et al. (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26(7), pp. 1054-1062. (doi: 10.1038/s41591-020-0900-x) (PMID:32461698)
Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)
Ferguson, J. et al. (2020) Staging by Thoracoscopy in Potentially Radically Treatable Non-Small Cell Lung Cancer Associated with Minimal Pleural Effusion (STRATIFY) study: a prospective multicentre study. Lung Cancer, 139(1), S92. (doi: 10.1016/S0169-5002(20)30245-2)
Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C. , Holme, J., Evison, M. and Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017) (PMID:31200818)
Cunningham, Y., Wyke, S. , Blyth, K. G. , Rigg, D., Macdonald, S. , Macleod, U., Harrow, S., Robb, K. A. and Whitaker, K. L. (2019) Lung cancer symptom appraisal among people with chronic obstructive pulmonary disease: a qualitative interview study. Psycho-Oncology, 28(4), pp. 718-725. (doi: 10.1002/pon.5005) (PMID:30693608) (PMCID:PMC6492269)
Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3(6), e000408. (doi: 10.1136/esmoopen-2018-000408) (PMID:30233821) (PMCID:PMC6135448)
Martin, G. A. , Tsim, S., Kidd, A. C., Foster, J. E., McLoone, P. , Chalmers, A. and Blyth, K. G. (2018) Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. BMJ Open Respiratory Research, 5(1), e000293. (doi: 10.1136/bmjresp-2018-000293) (PMID:29862030) (PMCID:PMC5976095)
Tsim, S. et al. (2018) Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy. Lung Cancer, 118, pp. 48-56. (doi: 10.1016/j.lungcan.2018.01.014) (PMID:29572002) (PMCID:PMC5884311)
Blyth, K. G. and Murphy, D. J. (2018) Progress and challenges in Mesothelioma: from bench to bedside. Respiratory Medicine, 134, pp. 31-41. (doi: 10.1016/j.rmed.2017.11.015)
Cherrie, J. W., McElvenny, D. and Blyth, K. G. (2018) Estimating past inhalation exposure to asbestos: a tool for risk attribution and disease screening. International Journal of Hygiene and Environmental Health, 221(1), pp. 27-32. (doi: 10.1016/j.ijheh.2017.09.013) (PMID:29030093)
Haughney, J., Morice, A., Blyth, K. G. , Lee, A. J., Coutts, A., McKnight, E. and Pavord, I. (2018) A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels. Respiratory Medicine, 134, pp. 117-123. (doi: 10.1016/j.rmed.2017.12.001) (PMID:29413497)
Kidd, A. C., McGettrick, M., Tsim, S., Halligan, D. L., Bylesjo, M. and Blyth, K. G. (2018) Survival prediction in mesothelioma using a scalable lasso regression model: instructions for use and initial performance using clinical predictors. BMJ Open Respiratory Research, 5(1), e000240. (doi: 10.1136/bmjresp-2017-000240) (PMID:29468073) (PMCID:PMC5812388)
Sharma, V. and Blyth, K. G. (2018) Empyema necessitans and a persistent air leak associated with rupture of an anaerobic lung abscess due to bacteroides. Thorax, 73(1), pp. 91-93. (doi: 10.1136/thoraxjnl-2017-210462) (PMID:28847872)
Evison, M. et al. (2018) Providing safe and effective pleural medicine services in the UK: an aspirational statement from UK pleural physicians. BMJ Open Respiratory Research, 5, e000307. (doi: 10.1136/bmjresp-2018-000307) (PMID:30116537) (PMCID:PMC6089266)
Murphy, D. J. and Blyth, K. G. (2017) Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'. Cell Death and Differentiation, 24(9), pp. 1473-1474. (doi: 10.1038/cdd.2017.97) (PMID:28622291)
Blyth, K. G. , Bellofiore, A., Jayasekera, G. , Foster, J. E., Steedman, T., Chesler, N. C. and Peacock, A. J. (2017) Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival. Pulmonary Circulation, 7(2), pp. 465-475. (doi: 10.1177/2045893217704838) (PMID:28597775) (PMCID:PMC5467938)
Tsim, S., Stobo, D. B., Alexander, L., Kelly, C. and Blyth, K. G. (2017) The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. Lung Cancer, 103, pp. 38-43. (doi: 10.1016/j.lungcan.2016.11.010) (PMID:28024694) (PMCID:PMC5226066)
Tsim, S. et al. (2016) Diagnostic and prognostic biomarkers in the rational assessment of mesothelioma (DIAPHRAGM) study: protocol of a prospective, multi-centre, observational study. BMJ Open, 6(11), e013324. (doi: 10.1136/bmjopen-2016-013324) (PMID:27884852) (PMCID:PMC5168514)
Blyth, K. G. (2015) Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax, 70(4), p. 374. (doi: 10.1136/thoraxjnl-2014-206464) (PMID:25480442)
Conference or Workshop Item
Neilly, M., Ferguson, K., Roche, J., Tate, M. and Blyth, K. (2024) Mesothelioma Evolution following a Diagnosis of Benign Pleural Inflammation: A Systematic Review and Meta-Analysis. 22nd Annual British Thoracic Oncology Group Conference, Belfast, UK, 17-19 April 2024. p. 107626. (doi: 10.1016/j.lungcan.2024.107626)
Armato, S. G., Blyth, K. G. , Keating, J. J., Katz, S., Tsim, S., Coolen, J., Gudmundsson, E., Opitz, I. and Nowak, A. K. (2016) Imaging in pleural mesothelioma: a review of the 13th International Conference of the International Mesothelioma Interest Group. 2016 International Conference of the International Mesothelioma Interest Group (iMig), Birmingham, UK, 01-04 May 2016. pp. 48-58. (doi: 10.1016/j.lungcan.2016.09.003)
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Pre-mesothelioma proteomic biomarkers for risk prediction and recruitment to future PREDICT-Meso clinical trials
NHS Greater Glasgow and Clyde Endowment Funds
2024 - 2025
- Translating Cutting-Edge Discovery Science into Patient Benefit
Medical Research Council
2023 - 2030
- Enabling sharing of Glasgow Cancer Data: an exemplar project aligned with the PREDICT-Meso Accelerator
Cancer Research UK
2023 - 2024
- FAMILC - Modelling the molecular link between high fat diet, metabolic reprogramming and inflammation in lung cancer
EPSRC EU Guarantee
2022 - 2025
- Integrated analysis from mouse to man for Early detection of Mesothelioma.
Cancer Research UK
2022 - 2027
- CRUK Centre Renewal 2021
Cancer Research UK
2022 - 2023
- Differential Expression in Bystander Transcriptomes for Mesothelioma Diagnosis: DEBiT-Meso
British Lung Foundation
2021 - 2024
- Improved analysis of data and prognosis in patients with Covid-19 using statistical analysis and deep machine learning
NHS Greater Glasgow and Clyde
2021 - 2023
- PREDICT-Meso: PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma
Cancer Research UK
2020 - 2021
- PREDICT-Meso: PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma
Cancer Research UK
2020 - 2022
- STRATIFY : Staging by Thoracoscopy in potentially Radically Treatable Non-Small Cell Lung Cancer associated with Minimal Pleural Effusion
Chief Scientist Office
2018 - 2021
- STRATIFY : Staging by Thoracoscopy in potentially Radically Treatable Non-Small Cell Lung Cancer associated with Minimal Pleural Effusion
Office of the Chief Scientific Adviser
2018 - 2023
- DIAPHRAGM Fibulin-3 Analysis
NHS Greater Glasgow and Clyde Endowment Funds
2018 - 2020
- DIAPHRAGM Sample Analysis
NHS Greater Glasgow and Clyde
2018 - 2020
- Meso-ORIGINS Feasibility Study
June Hancock Mesothelioma Research Fund
2018 - 2019
- BCC funded half of TRACERx fellow-K Blyth
Beatson Institute for Cancer Research
2017 - 2018
- CRUK TRACERx Lung Cancer Fellow
Cancer Research UK
2017 - 2018
- PRISM - Prediction of Resistance to chemotherapy using Somatic Copy Number Variation in Mesothelioma
British Lung Foundation
2017 - 2020
- DIAPHRAGM Sample Analysis
NHS Greater Glasgow and Clyde Endowment Funds
2015 - 2018
- An examination of diagnostic and prognostic biomarkers in malignant pleural mesothelioma
Chief Scientist Office
2013 - 2018
Research datasets
2021
Ross, K., Keith, N. , Jones, R. , Hanna, C. , Afzal, I., Basra, S., Bell, I., Bennie, M., Berger, A., Bilsland, A., Blyth, K. , Borris, A., Boruc, M., Bradley, J., Caryl, J., Cerniauskaite, U., Cheskin, L., Chiwanda, J., Cooper, J. , Debiasse, K., Fegan, S., Ferguson, C., Halsey, C. , Harris, F., Herceg, Z., Hogg, C., Hush, G., Julien, A., Kameda, R., Keith, A., Kelly, J., Konieczna, Z., Lu, M. Y., Mackay, S., Marinescu-Duca, M., Maxwell, M., McCaffrey, R., McGuire, N., McIntyre, D., Moffat-Kyle, T., Mukherjee, L., O'Friel, A., Perry, M. , Prentice, J., Prosser, Z., Proudfoot, B., Raman, S., Robinson, J. , Smith, A., Stewart, S., Stricevic, M., Teal, G., Thomson, H., Wang, Z., Welisch, G., Wu, O. , Wu, H., Young, E. and Young, S. (2021) The Future of Cancer and Collective Intelligence in the Post-Covid World. [Data Collection]